The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|October 29, 2023
2023 SDPA Fall Conference Recap: Day 4
Author(s)Emma Andrus, Associate Editor
Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.
Advertisement
Study Reveals HCPs Underestimate Burden of Disease Associated With Seborrheic Dermatitis
The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.
Understanding Itchy Dermatoses: Pearls and Best Practices
Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.
Mark Lebwohl, MD: The Evolving Treatment Landscape of IL-17 Inhibitors
Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.
Individualized Treatment Considerations for Adult Women With Acne
Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.
Make sure to keep up to date with the latest in coverage from the conference and subscribe to Dermatology Times to receive daily email updates .
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
2
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
3
FDA Revises TB Evaluation Guidance for SKYRIZI
4
Avoiding Common Mistakes When Escalating Therapy in Psoriasis
5